Furthermore, US Food and Drug Administration (FDA)-approved anti-PD-L1 antibody Pembrolizumab (Keytruda, Merck & Co., USA) is used for treating PD-L1+ recurrent or advanced GC patients with 2 or more prior lines of therapy [98,118]. Here, CD274 is linked to gastric cancer.